Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis
Xiaoting Wei,Yu Chen,Hong Yao,Di Wu,Hang Li,Rui Zhang,Zhihong Chi,Chuanliang Cui,Xue Bai,Lili Mao,Zhonghui Qi,Ke Li,Shijie Lan,Lizhu Chen,Rui Guo,Xinyu Yao,Bin Lian,Yan Kong,Jie Dai,Bixia Tang,Xuan Wang,Jun Guo,Lu Si,Jeffrey E. Gershenwald,Charles M. Balch
DOI: https://doi.org/10.1016/j.jaad.2022.08.052
IF: 15.487
2022-09-06
Journal of the American Academy of Dermatology
Abstract:Background Evidence for the prognostic importance of tumor thickness in acral melanoma (AM) patients is limited. Objective To determine the prognostic impact of Breslow thickness in AM. Methods This multicenter study enrolled patients diagnosed with localized AM between 1 January 2000 and 31 December 2017. Melanoma-specific survival (MSS) in different tumor thickness strata (T1−T4: ≤1, >1−2, >2−4, >4 mm, respectively) was estimated by Kaplan-Meier method. Comparisons were performed by log-rank test and multivariable Cox regression. Results A total of 853 patients with clinical N0 (cN0) AM were included in the analysis. The median follow-up time was 60.1 months. The median MSS in patients with T1–T4 disease was not reached, 111.0, 92.8, and 67.1 months, respectively. MSS differed significantly among cN0 patients with T1–T3 AM (log-rank P =0.004, 0.012, 2 mm. Limitations Retrospective design and some missing variables. Conclusions There was no association between tumor thickness and survival in AM patients with a Breslow thickness >2 mm
dermatology